CN107286101B - 1-芳醛肟尿嘧啶及其制备方法 - Google Patents

1-芳醛肟尿嘧啶及其制备方法 Download PDF

Info

Publication number
CN107286101B
CN107286101B CN201710622318.7A CN201710622318A CN107286101B CN 107286101 B CN107286101 B CN 107286101B CN 201710622318 A CN201710622318 A CN 201710622318A CN 107286101 B CN107286101 B CN 107286101B
Authority
CN
China
Prior art keywords
uracil
aldoxime
arh
preparation
aromatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201710622318.7A
Other languages
English (en)
Other versions
CN107286101A (zh
Inventor
金毅
林军
赵舒悦
蒋昆明
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yunnan University YNU
Original Assignee
Yunnan University YNU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yunnan University YNU filed Critical Yunnan University YNU
Priority to CN201710622318.7A priority Critical patent/CN107286101B/zh
Publication of CN107286101A publication Critical patent/CN107286101A/zh
Application granted granted Critical
Publication of CN107286101B publication Critical patent/CN107286101B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

一种1‑芳醛肟尿嘧啶及其制备方法，涉及药物领域，具体是一种抑制肿瘤细胞生长活性，具有显著地抑制胸苷磷酸化酶和抗肿瘤活性的1‑芳醛肟尿嘧啶及其制备方法。本发明的1‑芳醛肟尿嘧啶，其特征在于该化合物具有如下结构I：
Figure DDA0001361991290000011
其中，R1为甲基或氢，R2为氯、碘、羧基或氢，Ar为烷基苯基、卤代苯基、烷氧基苯基、噻吩基、呋喃基。本发明的1‑芳醛肟尿嘧啶及其制备方法，展示出很高的抑制肿瘤细胞生长活性，具有显著地抑制胸苷磷酸化酶和抗肿瘤活性的作用，制备过程简便，可行性高，便于大规模生产，有利于降低生产成本。

Description

1-芳醛肟尿嘧啶及其制备方法
技术领域
本发明涉及药物领域，具体是一种抑制肿瘤细胞生长活性，具有显著地抑制胸苷磷酸化酶和抗肿瘤活性的1-芳醛肟尿嘧啶及其制备方法。
背景技术
血管生成在肿瘤生长和转移的过程中扮演着十分重要的角色。胸苷磷酸化酶(TP)，是一种涉及到胸苷体内平衡和代谢的酶，由于其内皮细胞具有能够刺激内皮细胞迁移的趋向性运动从而被认为是依赖血管生成的。这种酶主要的功能是可以可逆的将胸苷磷酸化为胸腺嘧啶和2-脱氧核糖-1-磷酸盐，并活化5-氟尿嘧啶及前体。胸苷磷酸化酶不仅可以识别胸苷还可以识别脱氧尿苷和嘧啶核苷衍生物。根据基因序列比较，人类的胸苷磷酸化酶相当于血管生成蛋白质，内皮细胞血小板源生长因子。胸苷磷酸化酶和内皮细胞血小板源生长因子这类蛋白质都与胃癌、肾脏癌、子宫癌、平滑肌瘤、乳腺癌、结肠癌和肺癌有着不可分割的联系。
内皮细胞的迁移对于血管生成是十分重要的一步，而胸苷磷酸化酶的催化活性对于内皮细胞的迁移又十分重要，因此这些年来来有很多各种晶体结构的胸苷磷酸化酶及其类似物的阐述。近来，一系列含碱基或不含碱基的胸苷磷酸化酶抑制剂已经被合成和发表，并具有潜在的抗胸苷磷酸化酶活性及抗新生血管生成。在身体上，最有效的胸苷磷酸化酶抑制剂是尿嘧啶类衍生物，预期与胸苷上的位点相结合从而达到抑制的效果。目前最有效的抑制剂是5-氯-6-[1-(2-氨基吡咯)甲基]尿嘧啶磷酸盐(TPI),其IC50达到35nM，表现出了很好的抑制活性。与此同时，一系列无碱基的TP抑制剂已经合成并进行了测试，对其中一些化合物的作用机制进行了预测，它们是通过与TP的变构结合位点相互作用实现抑制作用，这有别于一般的底物位点结合。然而，在临床上长期使用同一种TP抑制剂可能会有毒性耐药性等副作用。为了解决这一问题应该进一步研究新的一系列的TP抑制剂。
胺肟是一类重要的有机物，其具有酰胺基肟的结构，常常被用作原料合成杂环及相关的中间体从而广泛的应用于制药、抗肿瘤剂、抗菌剂、抗炎剂等。胺肟的末端基团和TPI的氨基吡咯具有相似性，因此我们设计了目标分子。除了尿嘧啶单元外，新的胺肟结构有C＝N、N-OH、N-H、C＝O及不同的取代基，这些都有可能会与活性位点相结合从而实现抑制活性。
发明内容
本发明针对现有技术的不足，提供一种抑制肿瘤细胞生长活性，具有显著地抑制胸苷磷酸化酶和抗肿瘤活性的1-芳醛肟尿嘧啶及其制备方法。
本发明的1-芳醛肟尿嘧啶，其特征在于该化合物具有如下结构I：
Figure BDA0001361991280000021
其中，R1为甲基或氢，R2为氯、碘、羧基或氢，Ar为烷基苯基、卤代苯基、烷氧基苯基、噻吩基、呋喃基。
所述的1-芳醛肟尿嘧啶，为以下二十四种中的任意一种：
Figure BDA0001361991280000022
Figure BDA0001361991280000031
一种1-芳醛肟尿嘧啶的制备方法，其特征在于该制备方法的合成反应式为：
Figure BDA0001361991280000032
具体制备步骤如下：
(1)将芳香醛溶于甲醇中，常温下搅拌，待芳香醛完全溶解后，将盐酸羟胺和碳酸钾加入甲醇中，反应2-5h，反应完全后，萃取反应液，然后用饱和碳酸氢钠溶液进行洗涤，用无水硫酸钠干燥，减压蒸馏回收甲醇，得到芳香醛肟。
(2)将芳香醛肟溶于N,N-二甲基甲酰胺中，常温下搅拌，待芳香醛肟完全溶解后，加入NCS即氯代丁二酰亚胺，常温搅拌2-6h，反应完全后，萃取，利用饱和氯化钠溶液洗涤，用无水硫酸钠干燥，减压蒸馏除去溶剂，得到邻氯芳香醛肟；
(3)将邻氯芳香醛肟、取代尿嘧啶及碱溶解在有机溶剂1中，常温搅拌2-4h，待反应完全后，萃取、洗涤后，加入3-羧基苯甲醛，常温搅拌6h，析出白色固体，过滤、洗涤后，再用无水硫酸钠干燥，柱层析分离或重结晶，即可得到得1-芳醛肟尿嘧啶。
所述的步骤(3)中，有机溶剂1为甲醇、乙醇、异丙醇、乙酸乙酯、甲苯、四氢呋喃、甲苯、二氯甲烷、氯仿、1,4-二氧六环、N,N-二甲基甲酰胺或二甲基亚砜中的任意两种或两种以上溶剂的混合液。
所述的步骤(3)中，碱为氢氧化锂、氢氧化钠、氢氧化钾、碳酸钾、碳酸铯、磷酸钾、氟化铯、三乙胺中的一种或多种混合物。
本发明的1-芳醛肟尿嘧啶，其特征在于该化合物作为胸苷磷酸化酶的抑制剂，具有抑制胸苷磷酸化酶的活性，用于治疗胃癌、肾脏癌、子宫癌、平滑肌瘤、乳腺癌、结肠癌或肺癌。
本发明的1-芳醛肟尿嘧啶及其制备方法，展示出很高的抑制肿瘤细胞生长活性，具有显著地抑制胸苷磷酸化酶和抗肿瘤活性的作用，制备过程简便，可行性高，便于大规模生产，有利于降低生产成本。
具体实施方式
实施例1：一种1-芳醛肟尿嘧啶，具有如下结构I：
Figure BDA0001361991280000041
其中，R1为甲基或氢，R2为氯、碘、羧基或氢，Ar为烷基苯基、卤代苯基、烷氧基苯基、噻吩基、呋喃基。
该1-芳醛肟尿嘧啶，其结构式为：
Figure BDA0001361991280000051
1-芳醛肟尿嘧啶的制备方法，其合成反应式为：
Figure BDA0001361991280000052
R1＝CH3，H R2＝Cl，I，COOH，H
Figure BDA0001361991280000053
具体制备步骤如下：
(1)将0.02mol芳香醛溶于25mL甲醇中，常温下搅拌，待芳香醛完全溶解后，将0.02mol盐酸羟胺和0.022mol碳酸钾加入甲醇中，反应3h，反应完全后，萃取反应液，然后用饱和碳酸氢钠溶液进行洗涤，用无水硫酸钠干燥，减压蒸馏回收甲醇，得到芳香醛肟。
(2)将0.02mol芳香醛肟溶于25mL N,N-二甲基甲酰胺中，常温下搅拌，待芳香醛肟完全溶解后，加入0.022mol NCS，常温搅拌4h，反应完全后，萃取，利用饱和氯化钠溶液洗涤，用无水硫酸钠干燥，减压蒸馏除去溶剂，得到邻氯芳香醛肟；
(3)将2.4mmol邻氯芳香醛肟、2mmol取代尿嘧啶及2.4mmol氢氧化钠溶解在10mLN,N-二甲基甲酰胺与10mL甲醇的混合溶剂中，常温搅拌2-4h，待反应完全后，萃取、洗涤后，加入3-羧基苯甲醛，常温搅拌6h，析出白色固体，过滤、洗涤后，再用无水硫酸钠干燥，柱层析分离或重结晶，即可得到得1-芳醛肟尿嘧啶。
(Z)-1-(苯基)(肟基)甲基)-6-甲基嘧啶-2,4-(1H,3H)-二酮(化合物1)。
白色固体；M.p.245-246℃；IR(KBr,νmax,cm-1):3451,2918,1731,1658,1459,1367,1085,947,813,693,462；1H NMR(600MHz,DMSO-d6)(δ,ppm):12.35(s,1H,NH),11.48(s,1H,OH),7.63-7.61(m,J＝2.0Hz,2H,ArH),7.48-7.46(t,J＝7.0Hz,3H,ArH),5.72(s,1H,CH),1.89(s,3H,CH3)；13C NMR(150MHz,DMSO-d6)(δ,ppm):163.4,152.5,149.8,143.2,132.0,130.7,129.6,125.5,101.5,18.3；HRMS(ESI-TOF,[M+Na]+):m/z calcd for C12H11N3O3,268.0693；found,268.0687。
1、体外抗肿瘤实验：
采用的阳性参照化合物为7-去氮黄嘌呤(7DX)和5-氯-6-[1-(2-氨基吡咯)甲基]尿嘧啶磷酸盐(TPI)。
表1体外细胞水平的胸苷磷酸化酶抑制活性
Figure BDA0001361991280000061
药理结果显示，这类1-芳醛肟尿嘧啶化合物是一类高活性的肿瘤生长抑制剂，具有很强的抑制胸苷磷酸化酶的活性，尤其化合物4、5、6、7、12的IC50值达到0.12-9.7μM，显示出很高的抑制活性。
2、细胞毒素的实验
采用的参照化合物为环己酰亚胺。
选取对胸苷磷酸化酶具有较好抑制活性的化合物4、5、6、12，在小鼠成纤维细胞系上进行了细胞毒性，生长抑制能力评估。实验发现，所有的活性化合物在50μM的浓度以内都是无毒的。
实施例2：一种1-芳醛肟尿嘧啶，其结构式为
Figure BDA0001361991280000071
(Z)-1-((2-氟苯基)(肟基)甲基)-6-甲基嘧啶-2,4-(1H,3H)-二酮(化合物2)。
白色固体；M.p.248-249℃；IR(KBr,νmax,cm-1):3440,2919,1695,1432,1302,1179,989,811,512；1H NMR(600MHz,DMSO-d6)(δ,ppm):12.57(s,1H,NH),11.50(s,1H,OH),7.52-7.47(m,J＝7.6Hz,3H,ArH),7.46-7.33(m,1H,ArH),5.73(s,1H,CH),1.89(s,3H,CH3)；13CNMR(150MHz,DMSO-d6)(δ,ppm):163.4,162.1,152.3,149.8,142.5(d,3JC–F＝3Hz),134.6(d,3JC–F＝7.5Hz),131.7(d,3JC–F＝7.5Hz),121.7(d,3JC–F＝1.5Hz),117.6(d,2JC–F＝21Hz),112.3(d,2JC–F＝24Hz),101.8,18.3；HRMS(ESI-TOF,[M+H]+):m/z calcd for C12H10FN3O3,264.0779；found,264.0776。
实施例3：一种1-芳醛肟尿嘧啶，其结构式为
Figure BDA0001361991280000072
(Z)-1-((4-氟苯基)(肟基)甲基)-6-甲基嘧啶-2,4-(1H,3H)-二酮(化合物3)。
白色固体；M.p.234-235℃；IR(KBr,νmax,cm-1):3419,2921,1706,1513,1459,1159,841,605,538；1H NMR(500MHz,DMSO-d6)(δ,ppm):12.36(s,1H,NH),11.48(s,1H,OH),7.70-7.67(m,J＝8.5Hz,2H,ArH),7.31-7.28((m,J＝7Hz,2H,ArH),5.72(s,1H,CH),1.89(s,3H,CH3)；13C NMR(125MHz,DMSO-d6)(δ,ppm):163.4,162.7,152.4,149.8,142.5,128.7(d,3JC–F＝2.5Hz),128.0(d,3JC–F＝8.8Hz),116.7,116.5,101.6,18.3；HRMS(ESI-TOF,[M+H]+):m/z calcd for C12H10FN3O3,264.0779；found,264.0776。
实施例4：一种1-芳醛肟尿嘧啶，其结构式为
Figure BDA0001361991280000081
(Z)-1-((4-氯苯基)(肟基)甲基)-6-甲基嘧啶-2,4-(1H,3H)-二酮(化合物4)。
白色固体；M.p.249-250℃；IR(KBr,νmax,cm-1):3445,2922,1673,1493,1312,1093,942,836,705,504；1H NMR(600MHz,DMSO-d6)(δ,ppm):12.50(s,1H,NH),11.51(s,1H,OH),7.66-7.64(d,J＝8.6Hz,2H,ArH),7.53-7.52(d,J＝8.6Hz,2H,ArH),5.73(s,1H,CH),1.89(s,3H,CH3)；13C NMR(150MHz,DMSO-d6)(δ,ppm):163.4,152.4,149.8,142.5,135.3,131.0,129.6,127.4,101.7,18.3；HRMS(ESI-TOF,[M+H]+):m/z calcd for C12H10ClN3O3,280.0483；found,264.0480。
实施例5：一种1-芳醛肟尿嘧啶，其结构式为
Figure BDA0001361991280000082
(Z)-1-((肟基)(对甲苯基)甲基)-6-甲基嘧啶-2,4-(1H,3H)-二酮(化合物5)。
白色固体；M.p.256-257℃；IR(KBr,νmax,cm-1):3431,3287,2854,1671,1612,1408,1303,1185,941,823,706,531；1H NMR(500MHz,DMSO-d6)(δ,ppm):12.17(s,1H,NH),11.42(s,1H,OH),7.51-7.49(d,J＝8.5Hz,2H,ArH),7.28-7.26(d,J＝8Hz,2H,ArH),5.70(s,1H,CH),2.34(s,3H,CH3),1.88(s,3H,CH3)；13C NMR(150MHz,DMSO-d6)(δ,ppm):163.4,152.6,149.8,143.2,140.5,130.1,129.5,125.5,101.4,21.3,18.3；HRMS(ESI-TOF,[M+Na]+):m/zcalcd for C13H13N3O3,282.0849；found,282.0845。
实施例6：一种1-芳醛肟尿嘧啶，其结构式为
Figure BDA0001361991280000091
(Z)-1-((4-乙基苯基)(肟基)甲基)-6-甲基嘧啶-2,4-(1H,3H)-二酮(化合物6)。
白色固体；M.p.256-257℃；IR(KBr,νmax,cm-1):3444,3242,2964,1720,1656,1462,1370,1154,1020,950,849,526；1H NMR(500MHz,DMSO-d6)(δ,ppm):12.18(s,1H,NH),11.42(s,1H,OH),7.53-7.52(d,J＝8Hz,2H,ArH),7.31-7.29(d,J＝8Hz,2H,ArH),5.70(s,1H,CH),2.65-2.64(m,2H,CH2),1.89(s,3H,CH3),1.21-1.18(m,3H,CH3)；13C NMR(125MHz,DMSO-d6)(δ,ppm):163.4,152.6,149.8,146.7,143.2,129.6,128.9,125.6,101.4,28.4,18.3,15.8；HRMS(ESI-TOF,[M+H]+):m/z calcd for C14H15N3O3,274.1186；found,274.1182。
实施例7：一种1-芳醛肟尿嘧啶，其结构式为
Figure BDA0001361991280000092
(Z)-1-((4-溴苯基)(肟基)甲基)-6-甲基嘧啶-2,4-(1H,3H)-二酮(化合物7)。
白色固体；M.p.261-262℃；IR(KBr,νmax,cm-1):3426,1697,1672,1409,1310,1182,999,848,772,511；1H NMR(500MHz,DMSO-d6)(δ,ppm):12.51(s,1H,NH),11.51(s,1H,OH),7.72-7.70(m,J＝8.5Hz,2H,ArH),7.63-7.62(d,J＝8.5Hz,2H,ArH),5.76(s,1H,CH),1.94(s,3H,CH3)；13C NMR(125MHz,DMSO-d6)(δ,ppm):163.4,152.4,149.8,142.6,132.5,131.7,127.6,124.1,101.7,18.3；HRMS(ESI-TOF,[M+H]+):m/z calcd for C12H10BrN3O3,323.9984；found,323.9978。
实施例8：一种1-芳醛肟尿嘧啶，其结构式为
Figure BDA0001361991280000101
(Z)-1-((肟基)(3-甲氧基苯基)甲基)-6-甲基嘧啶-2,4-(1H,3H)-二酮(化合物8)。
白色固体；M.p.256-257℃；IR(KBr,νmax,cm-1):3427,3200,2922,1717,1659,1459,1385,1310,1236,1018,815,704；1H NMR(600MHz,DMSO-d6)(δ,ppm):12.37(s,1H,NH),11.47(s,1H,OH),7.38-7.37(m,J＝8Hz,1H,ArH),7.16-7.14(m,J＝2Hz,3H,ArH),5.72-5.71(d,1H,CH),3.80(s,3H,CH3),1.89(s,3H,CH3)；13C NMR(150MHz,DMSO-d6)(δ,ppm):163.4,160.1,152.5,149.8,143.1,133.5,130.8,118.0,116.4,110.5,101.5,55.7,18.3；HRMS(ESI-TOF,[M+H]+):m/z calcd for C13H13N3O4,276.0984；found,276.0978.
实施例9：一种1-芳醛肟尿嘧啶，其结构式为
Figure BDA0001361991280000102
(Z)-1-((4-乙基苯基)(肟基)甲基)-6-甲基嘧啶-2,4-(1H,3H)-二酮(化合物9)。
白色固体；M.p.243-244℃；IR(KBr,νmax,cm-1):3436,2920,1730,1669,1608,1450,1367,1181,1033,944,813,523；1H NMR(600MHz,DMSO-d6)(δ,ppm):12.05(s,1H,NH),11.43(s,1H,OH),7.55-7.54(d,J＝8.8Hz,2H,ArH),7.01-7.00(d,J＝8.8Hz,2H,ArH),5.69(s,1H,CH),3.80(s,3H,CH3),1.88(s,3H,CH3)；13C NMR(150MHz,DMSO-d6)(δ,ppm):163.4,161.3,152.6,149.8,143.0,127.1,124.5,115.0,101.4,55.8,18.3；HRMS(ESI-TOF,[M+H]+):m/z calcd for C13H13N3O4,276.0984；found,276.0982。
实施例10：一种1-芳醛肟尿嘧啶，其结构式为
Figure BDA0001361991280000111
(Z)-1-((肟基)(间甲苯基)甲基)-6-甲基嘧啶-2,4-(1H,3H)-二酮(化合物10)。
白色固体；M.p.246-247℃；IR(KBr,νmax,cm-1):3443,2920,1655,1480,1315,1022,923,802,711,507；1H NMR(600MHz,DMSO-d6)(δ,ppm):12.27(s,1H,NH),11.44(s,1H,OH),7.43(s,1H,ArH),7.41-7.40(d,J＝7.9Hz,1H,ArH),7.36-7.33(t,J＝7.7Hz,1H,ArH),7.30-7.29(d,J＝7.5Hz,1H,ArH),5.71(s,1H,CH),2.35(s,3H,CH3),1.89(s,3H,CH3)；13CNMR(150MHz,DMSO-d6)(δ,ppm):163.4,152.6,149.8,143.3,138.9,132.1,131.4,129.4,125.8,122.8,101.5,21.4,18.4；HRMS(ESI-TOF,[M+Na]+):m/z calcd for C13H13N3O3,282.0849；found,282.0844。
实施例11：一种1-芳醛肟尿嘧啶，其结构式为
Figure BDA0001361991280000112
(Z)-1-((3-氟苯基)(肟基)甲基)-6-甲基嘧啶-2,4-(1H,3H)-二酮(化合物11)。
白色固体；M.p.255-256℃；IR(KBr,νmax,cm-1):3439,3155,2766,1712,1616,1432,1296,1082,955,818,745,514；1H NMR(600MHz,DMSO-d6)(δ,ppm):12.49(s,1H,NH),11.41(s,1H,OH),7.45-7.42(m,J＝7.7Hz,3H,ArH),7.39-7.38(m,J＝7.3Hz,1H,ArH),7.28-7.26(t,J＝8Hz,1H,ArH)5.65(s,1H,CH),1.81(s,3H,CH3)；13C NMR(150MHz,DMSO-d6)(δ,ppm):163.4,162.1,152.3,149.8,142.5,134.7,131.8(d,3JC–F＝7.5Hz),121.7,117.6(d,2JC–F＝21Hz),112.3(d,2JC–F＝24Hz),101.8,18.3；HRMS(ESI-TOF,[M+H]+):m/z calcd forC12H10FN3O3,264.0779；found,264.0776。
实施例12：一种1-芳醛肟尿嘧啶，其结构式为
Figure BDA0001361991280000121
(Z)-1-((3,4-二氯苯基)(肟基)甲基)-6-甲基嘧啶-2,4-(1H,3H)-二酮(化合物12)。
白色固体；M.p.244-245℃；IR(KBr,νmax,cm-1):3428,2901,1755,1928,1367,1128,1025,892,655,543；1H NMR(600MHz,DMSO-d6)(δ,ppm):12.70(s,1H,NH),11.51(s,1H,OH),7.89(s,1H,ArH),7.74-7.73(d,J＝8.5Hz,1H,ArH),7.66-7.65(d,J＝8.5Hz,1H,ArH),5.73(s,1H,CH),2.35(s,3H,CH3),1.90(s,3H,CH3)；13C NMR(150MHz,DMSO-d6)(δ,ppm):163.4,152.2,149.9,141.8,133.3,132.9,132.5,131.8,127.2,125.8,102.0,18.3；HRMS(ESI-TOF,[M+H]+):m/z calcd for C12H9Cl2N3O3,314.0094；found,314.0088。
实施例13：一种1-芳醛肟尿嘧啶，其结构式为
Figure BDA0001361991280000122
(Z)-1-((肟基)(噻吩基)甲基)-6-甲基嘧啶-2,4-(1H,3H)-二酮(化合物13)。
黄色固体；M.p.234-235℃；IR(KBr,νmax,cm-1):3452,2901,1822,1652,1331,839,524；1H NMR(600MHz,DMSO-d6)(δ,ppm):12.08(s,1H,NH),11.43(s,1H,OH),7.82-7.81(m,1H,CH),7.67-7.65(m,1H,CH),7.42-7.41(m,1H,CH),5.69(s,1H,CH),1.90(s,3H,CH3)；13CNMR(150MHz,DMSO-d6)(δ,ppm):163.5,152.3,149.7,140.6,134.7,128.7,126.3,124.9,101.5,18.3。
实施例14：一种1-芳醛肟尿嘧啶，其结构式为
Figure BDA0001361991280000123
(E)-1-((肟基)(对甲苯基)甲基)-5-碘嘧啶-2,4-(1H,3H)-二酮(化合物14)。
白色固体；M.p.241-242℃；IR(KBr,νmax,cm-1):3438,3189,3049,2892,1720,1652,1408,1283,1140,1018,950,826,605,492；1H NMR(600MHz,DMSO-d6)(δ,ppm):12.14(s,1H,NH),11.90(s,1H,OH),8.10(s,1H,CH),7.51-7.49(d,J＝8.2Hz,2H,ArH),7.25-7.24(d,J＝8.1Hz,2H,ArH),2.33(s,3H,CH3)；13C NMR(150MHz,DMSO-d6)(δ,ppm):161.5,149.1,148.4,143.8,140.4,129.8,128.9,126.0,70.3,21.4；HRMS(ESI-TOF,[M+H]+):m/z calcd forC12H10IN3O3,371.9840；found,371.9838。
实施例15：一种1-芳醛肟尿嘧啶，其结构式为
Figure BDA0001361991280000131
(E)-1-((4-乙基苯基)(肟基)甲基)-5-碘嘧啶-2,4-(1H,3H)-二酮(化合物15)。
白色固体；M.p.238-240℃；IR(KBr,νmax,cm-1):3417,3187,3047,2965,2881,1720,1651,1603,1411,1285,1140,1014,949,841,606,530；1H NMR(500MHz,DMSO-d6)(δ,ppm):12.15(s,1H,NH),11.92(s,1H,OH),8.10(s,1H,CH),7.54-7.52(d,J＝7.5Hz,2H,ArH),7.28-7.27(d,J＝7.5Hz,2H,ArH),2.65-2.61(m,2H,CH2),1.19-1.16(t,3H,CH3)；13C NMR(125MHz,DMSO-d6)(δ,ppm):161.5,149.2,148.4,146.7,143.8,129.2,128.7,126.1,70.3,28.5,15.9；HRMS(ESI-TOF,[M+Na]+):m/z calcd for C12H11IN3O3,407.9821；found,407.9816。
实施例16：一种1-芳醛肟尿嘧啶，其结构式为
Figure BDA0001361991280000132
(E)-1-((2-氟苯基)(肟基)甲基)-5-碘嘧啶-2,4-(1H,3H)-二酮(化合物16)。
白色固体；M.p.249-250℃；IR(KBr,νmax,cm-1):3441,3052,2882,1724,1652,1601,1410,1306,1283,1139,1014,948,846,611,542；1H NMR(600MHz,DMSO-d6)(δ,ppm):12.48(s,1H,NH),11.91(s,1H,OH),8.11(s,1H,CH),7.49-7.48(m,J＝2.4Hz,3H,ArH),7.33-7.30(m,J＝2.4Hz,1H,ArH)；13C NMR(150MHz,DMSO-d6)(δ,ppm):163.6,162.0,161.5,149.2,148.1,143.1(d,3JC–F＝3Hz),134.3(d,3JC–F＝9Hz),131.4(d,3JC–F＝9Hz),122.3,117.5(d,2JC–F＝22.5Hz),112.9(d,2JC–F＝24Hz),70.7；HRMS(ESI-TOF,[M-H]-):m/z calcd forC11H7FIN3O3,373.9438；found,373.9442。
实施例17：一种1-芳醛肟尿嘧啶，其结构式为
Figure BDA0001361991280000141
(E)-1-((4-氯苯基)(肟基)甲基)-5-碘嘧啶-2,4-(1H,3H)-二酮(化合物17)。
白色固体；M.p.225-226℃；IR(KBr,νmax,cm-1):3440,3190,3048,2924,1727,1651,1601,1410,1307,1287,1095,948,832,770,511；1H NMR(600MHz,DMSO-d6)(δ,ppm):12.41(s,1H,NH),11.94(s,1H,OH),8.11(s,1H,CH),7.66-7.65(d,J＝8.6Hz,2H,ArH),7.50-7.49(m,J＝1.8Hz,2H,ArH)；13C NMR(150MHz,DMSO-d6)(δ,ppm):161.5,149.2,148.2,143.1,135.2,130.7,129.3,127.9,70.7；HRMS(ESI-TOF,[M+H]+):m/z calcd for C11H7ClIN3O3,391.9299；found,391.9294。
实施例18：一种1-芳醛肟尿嘧啶，其结构式为
Figure BDA0001361991280000142
(E)-1-((4-氟苯基)(肟基)甲基)-5-碘嘧啶-2,4-(1H,3H)-二酮(化合物18)。
白色固体；M.p.242-243℃；IR(KBr,νmax,cm-1):3440,3199,3052,2905,1728,1655,1600,1444,1305,1285,1214,1023,842,794,678,550；1H NMR(500MHz,DMSO-d6)(δ,ppm):12.29(s,1H,NH),11.92(s,1H,OH),8.12(s,1H,CH),7.70-7.68(m,J＝8.5Hz,2H,ArH),7.29-7.26(m,J＝9Hz,2H,ArH)；13C NMR(125MHz,DMSO-d6)(δ,ppm):164.5,162.8,161.5,149.2,148.3,143.1,128.5(t,2JC–F＝22.5Hz),115.8(d,2JC–F＝17.5Hz),70.5；HRMS(ESI-TOF,[M-H]-):m/z calcd for C11H7FIN3O3,373.9438；found,373.9444。
实施例19：一种1-芳醛肟尿嘧啶，其结构式为
Figure BDA0001361991280000151
(E)-1-((肟基)(4-甲氧基苯基)甲基)-5-碘嘧啶-2,4-(1H,3H)-二酮(化合物19)。
黄色固体；M.p.245-246℃；IR(KBr,νmax,cm-1):3189,3050,2894,1722,1655,1521,1415,1345,1285,1178,1013,948,836,638,542；1H NMR(600MHz,DMSO-d6)(δ,ppm):12.00(s,1H,NH),11.89(s,1H,OH),8.08(s,1H,CH),7.56-7.54(d,J＝8.8Hz,2H,ArH),6.99-6.98(d,J＝8.9Hz,2H,ArH),3.79(s,3H,CH3)；13C NMR(150MHz,DMSO-d6)(δ,ppm):161.5,161.3,149.1,148.4,143.6,127.7,124.1,114.7,70.2,55.9；HRMS(ESI-TOF,[M+H]+):m/z calcdfor C11H10IN3O4,387.9789；found,387.9787。
实施例20：一种1-芳醛肟尿嘧啶，其结构式为
Figure BDA0001361991280000152
(E)-1-((肟基)(苯基)甲基)-5-碘嘧啶-2,4-(1H,3H)-二酮(化合物20)。
白色固体；M.p.253-254℃；IR(KBr,νmax,cm-1):3443,3087,3051,2916,1722,1649,1439,1285,1015,949,781,610；1H NMR(500MHz,DMSO-d6)(δ,ppm):12.28(s,1H,NH),11.93(s,1H,OH),8.13(s,1H,CH),7.62-7.61(d,2H,ArH),7.48-7.42(m,2H,ArH)；13C NMR(125MHz,DMSO-d6)(δ,ppm):161.5,149.2,148.4,143.8,131.7,130.6,129.3,126.1,70.5；HRMS(ESI-TOF,[M+Na]+):m/z calcd for C11H8IN3O3,379.9308；found,379.9504。
实施例21：一种1-芳醛肟尿嘧啶，其结构式为
Figure BDA0001361991280000161
(E)-1-((肟基)(3-甲氧基苯基)甲基)-5-碘嘧啶-2,4-(1H,3H)-二酮(化合物21)。
黄色固体；M.p.255-256℃；IR(KBr,νmax,cm-1):3478,3072,2894,1738,1608,1434,1218,1138,1044,940,756,636,549；1H NMR(600MHz,DMSO-d6)(δ,ppm):12.31(s,1H,NH),11.92(s,1H,OH),8.11(s,1H,CH),7.36-7.35(t,1H,ArH),7.16-7.14(m,2H,ArH),7.07-7.05(t,1H,ArH),3.79(s,3H,CH3)；13C NMR(150MHz,DMSO-d6)(δ,ppm):161.9,151.7,149.2,148.3,143.7,133.1,130.5,118.6,116.3,111.2,55.8；HRMS(ESI-TOF,[M-H]-):m/zcalcd for C12H10IN3O4,385.9638；found,385.9645。
实施例22：一种1-芳醛肟尿嘧啶，其结构式为
Figure BDA0001361991280000162
(E)-5-氯-3-((肟基)(对甲苯基)甲基)-4-甲基吡啶-2,6(1H,3H)-二酮(化合物22)。
白色固体；1H NMR(600MHz,DMSO-d6)(δ,ppm):12.32(s,1H,NH),11.05(s,1H,OH),7.60-7.58(d,J＝8.2Hz,2H,ArH),7.27-7.26(d,J＝8.1Hz,2H,ArH),2.38-2.33(m,3H,CH3),2.20-2.19(d,3H,CH3)；13C NMR(150MHz,DMSO-d6)(δ,ppm):159.3,148.9,148.3,143.2,140.7,130.3,130.1,129.0,126.5,125.7,107.6,21.4,16.8.l。
实施例23：一种1-芳醛肟尿嘧啶，其结构式为
Figure BDA0001361991280000163
(E)-5-((肟基)(对甲苯基)甲基)-2,6-二酮-1,2,5,6-四氢吡啶-3-羧酸(化合物23)。
白色固体；1H NMR(600MHz,DMSO-d6)(δ,ppm):15.12(s,1H,COOH),12.32(s,1H,NH),11.05(s,1H,OH),8.13(s,1H,CH),7.72-7.70(d,2H,ArH),7.26-7.25(d,2H,ArH),2.57(s,3H,CH3)。
实施例24：一种1-芳醛肟尿嘧啶，其结构式为
Figure BDA0001361991280000171
(E)-5-氟-3-((肟基)(对甲苯基)甲基)吡啶-2,6-(1H,3H)-二酮(化合物24)。
白色固体；1H NMR(600MHz,DMSO-d6)(δ,ppm):11.01(s,1H,NH),10.23(s,1H,OH),7.56(s,1H,CH),7.28-7.27(m,2H,ArH),7.71-7.70(m,2H,ArH),2.57(s,3H,CH3)。

Claims (6)

1.一种1-芳醛肟尿嘧啶，其特征在于该化合物具有如下结构I：
Figure FDA0002287645380000011
其中，R1为甲基或氢，R2为氯、碘、羧基或氢，Ar为烷基苯基、卤代苯基、烷氧基苯基、噻吩基、呋喃基。
2.如权利要求1所述的1-芳醛肟尿嘧啶，其特征在于该化合物为以下二十一种中的任意一种：
Figure FDA0002287645380000012
Figure FDA0002287645380000021
3.一种1-芳醛肟尿嘧啶的制备方法，其特征在于该制备方法的合成反应式为：
Figure FDA0002287645380000022
具体制备步骤如下：
(1)将芳香醛溶于甲醇中，常温下搅拌，待芳香醛完全溶解后，将盐酸羟胺和碳酸钾加入甲醇中，反应2-5h，反应完全后，萃取反应液，然后用饱和碳酸氢钠溶液进行洗涤，用无水硫酸钠干燥，减压蒸馏回收甲醇，得到芳香醛肟。
(2)将芳香醛肟溶于N,N-二甲基甲酰胺中，常温下搅拌，待芳香醛肟完全溶解后，加入NCS即氯代丁二酰亚胺，常温搅拌2-6h，反应完全后，萃取，利用饱和氯化钠溶液洗涤，用无水硫酸钠干燥，减压蒸馏除去溶剂，得到邻氯芳香醛肟；
(3)将邻氯芳香醛肟、取代尿嘧啶及碱溶解在有机溶剂1中，常温搅拌2-4h，待反应完全后，萃取、洗涤后，加入3-羧基苯甲醛，常温搅拌6h，析出白色固体，过滤、洗涤后，再用无水硫酸钠干燥，柱层析分离或重结晶，即可得到得1-芳醛肟尿嘧啶。
4.如权利要求3所述的1-芳醛肟尿嘧啶的制备方法，其特征在于所述的步骤(3)中，有机溶剂1为甲醇、乙醇、异丙醇、乙酸乙酯、甲苯、四氢呋喃、二氯甲烷、氯仿、1,4-二氧六环、N,N-二甲基甲酰胺或二甲基亚砜中的任意两种或两种以上溶剂的混合液。
5.如权利要求3所述的1-芳醛肟尿嘧啶的制备方法，其特征在于所述的步骤(3)中，碱为氢氧化锂、氢氧化钠、氢氧化钾、碳酸钾、碳酸铯、磷酸钾、氟化铯、三乙胺中的一种或多种混合物。
6.如权利要求1所述的1-芳醛肟尿嘧啶，其特征在于该化合物作为胸苷磷酸化酶的抑制剂，具有抑制胸苷磷酸化酶的活性，用于治疗胃癌、肾脏癌、子宫癌、平滑肌瘤、乳腺癌、结肠癌或肺癌。
CN201710622318.7A 2017-07-27 2017-07-27 1-芳醛肟尿嘧啶及其制备方法 Expired - Fee Related CN107286101B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710622318.7A CN107286101B (zh) 2017-07-27 2017-07-27 1-芳醛肟尿嘧啶及其制备方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201710622318.7A CN107286101B (zh) 2017-07-27 2017-07-27 1-芳醛肟尿嘧啶及其制备方法

Publications (2)

Publication Number Publication Date
CN107286101A CN107286101A (zh) 2017-10-24
CN107286101B true CN107286101B (zh) 2020-04-21

Family

ID=60103126

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201710622318.7A Expired - Fee Related CN107286101B (zh) 2017-07-27 2017-07-27 1-芳醛肟尿嘧啶及其制备方法

Country Status (1)

Country Link
CN (1) CN107286101B (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111533700B (zh) * 2020-05-20 2023-03-28 天津科技大学 一种5-取代的尿嘧啶衍生物及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1659148A (zh) * 2002-06-10 2005-08-24 默克专利有限公司 芳基肟化合物
CN102503953A (zh) * 2011-10-20 2012-06-20 天津药物研究院 肟类化合物
CN106883217A (zh) * 2017-04-01 2017-06-23 清华大学深圳研究生院 一种核苷碱基异羟肟酸衍生化合物及其制备方法与应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA89035C2 (ru) * 2003-12-03 2009-12-25 Лео Фарма А/С Эфиры гидроксамовых кислот и их фармацевтическое применение

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1659148A (zh) * 2002-06-10 2005-08-24 默克专利有限公司 芳基肟化合物
CN102503953A (zh) * 2011-10-20 2012-06-20 天津药物研究院 肟类化合物
CN106883217A (zh) * 2017-04-01 2017-06-23 清华大学深圳研究生院 一种核苷碱基异羟肟酸衍生化合物及其制备方法与应用

Also Published As

Publication number Publication date
CN107286101A (zh) 2017-10-24

Similar Documents

Publication Publication Date Title
JP6514398B2 (ja) メチル｛４，６−ジアミノ−２−［１−（２−フルオロベンジル）−１Ｈ−ピラゾロ［３，４−ｂ］ピリジン−３−イル］ピリミジン−５−イル｝メチルカルバメートの調製方法および医薬上活性な化合物として用いるためのその精製方法
US7407961B2 (en) Pyrazine derivatives and pharmaceutical use thereof
JP4978192B2 (ja) ピラジン誘導体およびその医薬的使用
EP1530568B1 (de) INDOL-ODER BENZIMIDAZOLDERIVATE ZUR MODULATION DER IkB-KINASE
EP3319963B1 (en) Substituted 4-azaindoles and their use as glun2b receptor modulators
CA3062294A1 (en) Non-fused tricyclic compounds
AU2018267545A1 (en) Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
US20090186876A1 (en) Pyridine Analogues II
EP3375780A1 (en) Heterocyclic amides as kinase inhibitors
US20040229889A1 (en) HDAC inhibitor
AU2013307328A1 (en) Fused bicyclic sulfamoyl derivatives and the use thereof as medicaments for the treatment of hepatitis B
MX2011000738A (es) 3,4-diarilpirazoles como inhibidoers de proteina cinasa.
WO1995035298A1 (fr) DERIVE DE PYRAZOLO[1,5-a]PYRIMIDINE
CA2484209A1 (en) Protein kinase modulators and methods of use
JP2019524676A (ja) 新規な４−アミノピラゾロ［３，４−ｄ］ピリミジニルアザビシクロ誘導体およびこれを含む薬学組成物
MXPA04011417A (es) Derivados de aminoindazol activos como inhibidores de cinasa, procedimiento para su preparacion y composiciones farmaceuticas que los comprenden.
EP2933248B1 (en) Novel renin inhibitor
KR20180012861A (ko) 브로모도메인 억제제로서의 스피로[사이클로부탄-1,3'-인돌린]-2'-온 유도체
FR2919869A1 (fr) Nouveaux derives de n, n'-2,4-dianilinopyrimidines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
HU200337B (en) Process for producing substituted 6-phenyldihydro-3/2h/-pyridazinone derivatives and pharmaceutical compositions comprising such compounds
TW200306834A (en) Aminopyrimidine compound and pharmaceutical use thereof
CN100402521C (zh) 4-咪唑啉-2-酮化合物
WO2021115375A1 (zh) 含氮杂环类自分泌运动因子抑制剂及其组合物和用途
CN107286101B (zh) 1-芳醛肟尿嘧啶及其制备方法
CA2674998A1 (en) Pyridine compounds and their use as p2y12 antagonists

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20200421

Termination date: 20210727